

## Supporting Information

### **Koilodenoids A–G, Immunosuppressive Spiro Dimers of Diterpenoids from *Koilodepas hainanense*: Structural Elucidation and Biomimetic Transformation**

Yu Ren,<sup>‡a</sup> Cheng-Yu Zheng,<sup>‡a</sup> Jia-Ying Yao,<sup>c</sup> Shi-Jun He,<sup>\*c</sup> Yao-Yue Fan<sup>\*a</sup> and Jian-Min Yue<sup>\*ab</sup>

a. State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China. E-mail: s040500290@126.com; jmyue@simm.ac.cn

b. Units of Discovery of New Drug Lead Molecules, Chinese Academy of Medical Sciences, Shanghai 201203, China

c. Innovation Research Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, 1200 Cailun Road, Shanghai 201203, China. E-mail: heshijun@shutcm.edu.cn

<b>Structure elucidation for compounds 5–7</b> .....	5
<b>Table S1.</b> <sup>1</sup> H (400 MHz) and <sup>13</sup> C (125 MHz) NMR Data for Compound <b>2</b> in CDCl <sub>3</sub> .....	7
<b>Table S2.</b> <sup>1</sup> H (400 MHz) and <sup>13</sup> C (125 MHz) NMR Data for Compound <b>3</b> in CDCl <sub>3</sub> .....	8
<b>Table S3.</b> <sup>1</sup> H (400 MHz) and <sup>13</sup> C (125 MHz) NMR Data for Compound <b>4</b> in CDCl <sub>3</sub> .....	9
<b>Table S4.</b> <sup>1</sup> H (400 MHz) and <sup>13</sup> C (125 MHz) NMR Data for Compound <b>5</b> in CDCl <sub>3</sub> .....	10
<b>Table S5.</b> <sup>1</sup> H (400 MHz) and <sup>13</sup> C (125 MHz) NMR Data for Compound <b>6</b> in CDCl <sub>3</sub> .....	11
<b>Table S6.</b> <sup>1</sup> H (400 MHz) and <sup>13</sup> C (125 MHz) NMR Data for Compound <b>7</b> in CDCl <sub>3</sub> .....	12
<b>Table S7.</b> X-ray Crystallographic Data for Compound <b>2</b> <sup>a</sup> .....	13
<b>Table S8.</b> X-ray Crystallographic Data for Compound <b>3</b> <sup>a</sup> .....	14
<b>Table S9.</b> X-ray Crystallographic Data for Compound <b>4</b> <sup>a</sup> .....	15
<b>Table S10.</b> X-ray Crystallographic Data for Compound <b>7</b> <sup>a</sup> .....	16
<b>Scheme S1. Plausible biosynthetic pathway for 1–4</b> .....	17
<b>Figure S1.</b> Key COSY, HMBC, and NOESY correlations of <b>2</b> . .....	17
<b>Figure S2.</b> Key COSY, HMBC, and NOESY correlations of <b>3</b> . .....	18
<b>Figure S3.</b> Key COSY, HMBC, and NOESY correlations of <b>4</b> . .....	19
<b>Figure S4.</b> Key COSY, HMBC, and NOESY correlations of <b>5</b> . .....	19
<b>Figure S5.</b> The ECD spectra of compounds <b>4–6</b> . .....	20
<b>Figure S6.</b> ECD spectra of compound <b>5</b> in a DMSO solution (blue) and in a DMSO solution of Mo <sub>2</sub> (OAc) <sub>4</sub> (red) (The inherent ECD was subtracted). .....	20
<b>Figure S7.</b> Key COSY, HMBC, and NOESY correlations of <b>6</b> . .....	21
<b>Figure S8.</b> Key COSY, HMBC, and NOESY correlations of <b>7</b> . .....	22
<b>Figure S9.</b> X-ray ORTEP drawing of <b>7</b> . .....	22
<b>Figure S10.</b> <sup>1</sup> H NMR spectrum of natural Koilodenoid A ( <b>1</b> ) in CDCl <sub>3</sub> . .....	23
<b>Figure S11.</b> <sup>13</sup> C NMR spectrum of natural Koilodenoid A ( <b>1</b> ) in CDCl <sub>3</sub> . .....	24
<b>Figure S12.</b> HSQC spectrum of natural Koilodenoid A ( <b>1</b> ) in CDCl <sub>3</sub> .....	25
<b>Figure S13.</b> <sup>1</sup> H- <sup>1</sup> H COSY NMR spectrum of natural Koilodenoid A ( <b>1</b> ) in CDCl <sub>3</sub> . .....	26
<b>Figure S14.</b> HMBC spectrum of natural Koilodenoid A ( <b>1</b> ) in CDCl <sub>3</sub> .....	27
<b>Figure S15.</b> NOESY spectrum of natural Koilodenoid A ( <b>1</b> ) in CDCl <sub>3</sub> . .....	28
<b>Figure S16.</b> (+)-ESIMS spectrum of natural Koilodenoid A ( <b>1</b> ). .....	29
<b>Figure S17.</b> (+)-HRESIMS spectrum of natural Koilodenoid A ( <b>1</b> ). .....	30

<b>Figure S18.</b> IR spectrum of natural Koilodenoid A ( <b>1</b> ).....	31
<b>Figure S19.</b> <sup>1</sup> H NMR spectrum of Koilodenoid B ( <b>2</b> ) in CDCl <sub>3</sub> . ....	32
<b>Figure S20.</b> <sup>13</sup> C NMR spectrum of Koilodenoid B ( <b>2</b> ) in CDCl <sub>3</sub> . ....	33
<b>Figure S21.</b> HSQC spectrum of Koilodenoid B ( <b>2</b> ) in CDCl <sub>3</sub> . ....	34
<b>Figure S22.</b> <sup>1</sup> H- <sup>1</sup> H COSY spectrum of Koilodenoid B ( <b>2</b> ) in CDCl <sub>3</sub> . ....	35
<b>Figure S23.</b> HMBC spectrum of Koilodenoid B ( <b>2</b> ) in CDCl <sub>3</sub> .....	36
<b>Figure S24.</b> NOESY spectrum of Koilodenoid B ( <b>2</b> ) in CDCl <sub>3</sub> . ....	37
<b>Figure S25.</b> (+)-ESIMS spectrum of Koilodenoid B ( <b>2</b> ). ....	38
<b>Figure S26.</b> (+)-HRESIMS spectrum of Koilodenoid B ( <b>2</b> ).....	39
<b>Figure S27.</b> IR spectrum of Koilodenoid B ( <b>2</b> ). ....	40
<b>Figure S28.</b> <sup>1</sup> H NMR spectrum of Koilodenoid C ( <b>3</b> ) in CDCl <sub>3</sub> . ....	41
<b>Figure S29.</b> <sup>13</sup> C NMR spectrum of Koilodenoid C ( <b>3</b> ) in CDCl <sub>3</sub> . ....	42
<b>Figure S30.</b> HSQC spectrum of Koilodenoid C ( <b>3</b> ) in CDCl <sub>3</sub> . ....	43
<b>Figure S31.</b> <sup>1</sup> H- <sup>1</sup> H COSY NMR spectrum of Koilodenoid C ( <b>3</b> ) in CDCl <sub>3</sub> . ....	44
<b>Figure S32.</b> HMBC spectrum of Koilodenoid C ( <b>3</b> ) in CDCl <sub>3</sub> .....	45
<b>Figure S33.</b> NOESY spectrum of Koilodenoid C ( <b>3</b> ) in CDCl <sub>3</sub> . ....	46
<b>Figure S34.</b> (+)-ESIMS spectrum of Koilodenoid C ( <b>3</b> ). ....	47
<b>Figure S35.</b> (+)-HRESIMS spectrum of Koilodenoid C ( <b>3</b> ).....	48
<b>Figure S36.</b> IR spectrum of Koilodenoid C ( <b>3</b> ). ....	49
<b>Figure S37.</b> <sup>1</sup> H NMR spectrum of Koilodenoid D ( <b>4</b> ) in CDCl <sub>3</sub> . ....	50
<b>Figure S38.</b> <sup>13</sup> C NMR spectrum of Koilodenoid D ( <b>4</b> ) in CDCl <sub>3</sub> . ....	51
<b>Figure S39.</b> HSQC spectrum of Koilodenoid D ( <b>4</b> ) in CDCl <sub>3</sub> .....	52
<b>Figure S40.</b> <sup>1</sup> H- <sup>1</sup> H COSY NMR spectrum of Koilodenoid D ( <b>4</b> ) in CDCl <sub>3</sub> . ....	53
<b>Figure S41.</b> HMBC spectrum of Koilodenoid D ( <b>4</b> ) in CDCl <sub>3</sub> .....	54
<b>Figure S42.</b> NOESY spectrum of Koilodenoid D ( <b>4</b> ) in CDCl <sub>3</sub> . ....	55
<b>Figure S43.</b> (+)-ESIMS spectrum of Koilodenoid D ( <b>4</b> ). ....	56
<b>Figure S44.</b> (+)-HRESIMS spectrum of Koilodenoid D ( <b>4</b> ).....	57
<b>Figure S45.</b> IR spectrum of Koilodenoid D ( <b>4</b> ). ....	58
<b>Figure S46.</b> <sup>1</sup> H NMR spectrum of Koilodenoid E ( <b>5</b> ) in CDCl <sub>3</sub> .....	59
<b>Figure S47.</b> <sup>13</sup> C NMR spectrum of Koilodenoid E ( <b>5</b> ) in CDCl <sub>3</sub> .....	60
<b>Figure S48.</b> HSQC spectrum of Koilodenoid E ( <b>5</b> ) in CDCl <sub>3</sub> . ....	61
<b>Figure S49.</b> <sup>1</sup> H- <sup>1</sup> H COSY NMR spectrum of Koilodenoid E ( <b>5</b> ) in CDCl <sub>3</sub> .....	62

<b>Figure S50.</b> HMBC spectrum of Koilodenoid E ( <b>5</b> ) in CDCl <sub>3</sub> .....	63
<b>Figure S51.</b> NOESY spectrum of Koilodenoid E ( <b>5</b> ) in CDCl <sub>3</sub> .....	64
<b>Figure S52.</b> (+)-ESIMS spectrum of Koilodenoid E ( <b>5</b> ).....	65
<b>Figure S53.</b> (+)-HRESIMS spectrum of Koilodenoid E ( <b>5</b> ).....	66
<b>Figure S54.</b> IR spectrum of Koilodenoid E ( <b>5</b> ).....	67
<b>Figure S55.</b> <sup>1</sup> H NMR spectrum of Koilodenoid F ( <b>6</b> ) in CDCl <sub>3</sub> .....	68
<b>Figure S56.</b> <sup>13</sup> C NMR spectrum of Koilodenoid F ( <b>6</b> ) in CDCl <sub>3</sub> .....	69
<b>Figure S57.</b> HSQC spectrum of Koilodenoid F ( <b>6</b> ) in CDCl <sub>3</sub> .....	70
<b>Figure S58.</b> <sup>1</sup> H- <sup>1</sup> H COSY NMR spectrum of Koilodenoid F ( <b>6</b> ) in CDCl <sub>3</sub> .....	71
<b>Figure S59.</b> HMBC spectrum of Koilodenoid F ( <b>6</b> ) in CDCl <sub>3</sub> .....	72
<b>Figure S60.</b> NOESY spectrum of Koilodenoid F ( <b>6</b> ) in CDCl <sub>3</sub> .....	73
<b>Figure S61.</b> (+)-ESIMS spectrum of Koilodenoid F ( <b>6</b> ).....	74
<b>Figure S62.</b> (+)-HRESIMS spectrum of Koilodenoid F ( <b>6</b> ).....	75
<b>Figure S63.</b> IR spectrum of Koilodenoid F ( <b>6</b> ).....	76
<b>Figure S64.</b> <sup>1</sup> H NMR spectrum of Koilodenoid G ( <b>7</b> ) in CDCl <sub>3</sub> .....	77
<b>Figure S65.</b> <sup>13</sup> C NMR spectrum of Koilodenoid G ( <b>7</b> ) in CDCl <sub>3</sub> .....	78
<b>Figure S66.</b> HSQC spectrum of Koilodenoid G ( <b>7</b> ) in CDCl <sub>3</sub> .....	79
<b>Figure S67.</b> <sup>1</sup> H- <sup>1</sup> H COSY NMR spectrum of Koilodenoid G ( <b>7</b> ) in CDCl <sub>3</sub> .....	80
<b>Figure S68.</b> HMBC spectrum of Koilodenoid G ( <b>7</b> ) in CDCl <sub>3</sub> .....	81
<b>Figure S69.</b> NOESY spectrum of Koilodenoid G ( <b>7</b> ) in CDCl <sub>3</sub> .....	82
<b>Figure S70.</b> (+)-ESIMS spectrum of Koilodenoid G ( <b>7</b> ).....	83
<b>Figure S71.</b> (+)-HRESIMS spectrum of Koilodenoid G ( <b>7</b> ).....	84
<b>Figure S72.</b> IR spectrum of Koilodenoid G ( <b>7</b> ).....	85
<b>Figure S73.</b> <sup>1</sup> H NMR spectrum of compound <b>9</b> in CDCl <sub>3</sub> .....	86
<b>Figure S74.</b> <sup>13</sup> C NMR spectrum of compound <b>9</b> in CDCl <sub>3</sub> .....	87
<b>Figure S75.</b> (+)-HRESIMS spectrum of compound <b>9</b> .....	88
<b>Figure S76.</b> <sup>1</sup> H NMR spectrum of synthetic Koilodenoid A ( <b>1</b> ) in CDCl <sub>3</sub> .....	89
<b>Figure S77.</b> <sup>13</sup> C NMR spectrum of synthetic Koilodenoid A ( <b>1</b> ) in CDCl <sub>3</sub> .....	90
<b>Figure S78.</b> (+)-HRESIMS spectrum of synthetic Koilodenoid A ( <b>1</b> ).....	91

## Structure elucidation for compounds 5–7

Koilonoid E (**5**) had a molecular formula of  $C_{40}H_{62}O_6$  as deduced from the HRESIMS and  $^{13}C$  NMR data. The NMR data of **5** (Table S4) resembled those of **4**, except that the chloride group at C-16' in **4** was replaced by a hydroxy group in **5**, which was supported by the relatively downfield chemical shift of C-16' ( $\delta_C$  62.7 in **5** vs  $\delta_C$  48.3 in **4**) and the  $^1H$ - $^1H$  COSY correlations of H-15'/H<sub>2</sub>-16' (Figure S4). The relative and absolute configurations of **5** except for C-15', were elucidated to be identical to those of **4** based on the NOESY data (Figure S4B) and three highly compatible ECD curves (Figure S5). Finally, the absolute configuration of C-15' was determined as *R* by Snatzke's method. As shown in Figure S6, the ECD spectrum of compound **5** and  $Mo_2(OAc)_4$  in DMSO exhibits a negative Cotton effect at 310 nm, corresponding to a negative dihedral angle of the O–C–C–O moiety.

Koilonoid F (**6**) gave a molecular formula of  $C_{40}H_{58}O_7$ . Comparison of the 1D NMR data of compounds **6** and **2** (Tables S1 and S5) revealed their structural closeness. In-depth scrutiny of the NMR data (Figure S7), especially the HMBC correlations from H-1 and H-10 to C-2 ( $\delta_C$  193.1) and the downfield chemical shift of C-4 ( $\delta_C$  143.2 in **6** vs  $\delta_C$  116.8 in **2**), revealed that an additional carbonyl was located at C-2 and conjugated to the  $\Delta^3$  double bond in **6**. Correspondingly, an absorption band at  $\lambda_{max}$  276 nm in the UV spectrum (Figure S5) and two absorption peaks at 1676 and 1620  $cm^{-1}$  in the IR spectrum further confirmed the presence of an enone moiety in **6**. The absolute configuration of **6** was determined as delineated by comparison of the ECD spectra (Figure S5). Compound **6** was therefore identified as a 2-oxo derivative of **2**.

Koilonoid G (**7**) exhibited a molecular formula of  $C_{39}H_{58}O_6$ . The  $^1H$  and  $^{13}C$  NMR data of **7** (Table S6) were very similar to those of **2**, except for the presence of a carboxyl

group at  $\delta_C$  184.8 and the disappearance of an  $\alpha$ -hydroxy ketone motif in **7**. The carboxyl group was assigned to C-15 based on the HMBC correlation from H<sub>3</sub>-17 to C-15 (Figure S8). The absolute configuration of **7** was established as 5*R*, 8*S*, 9*S*, 10*R*, 13*S*, 4'*R*, 5'*R*, 8'*S*, 9'*S*, 10'*R*, 13'*S* by single-crystal X-ray diffraction with a Flack parameter of 0.06 (10) (Figure S9).

**Table S1.**  $^1\text{H}$  (400 MHz) and  $^{13}\text{C}$  (125 MHz) NMR Data for Compound **2** in  $\text{CDCl}_3$ .

No.	$\delta_{\text{H}}$ , multiplets ( $J$ in Hz)	$\delta_{\text{C}}$ , type	No.	$\delta_{\text{H}}$ , multiplets ( $J$ in Hz)	$\delta_{\text{C}}$ , type
1	1.46, m 1.65, overlap	17.5, $\text{CH}_2$	1'	1.55, m 1.91, m	23.5, $\text{CH}_2$
2	1.99, overlap 2.20, m	29.6, $\text{CH}_2$	2'	2.08, m 2.70, m	38.3, $\text{CH}_2$
3		143.6, C	3'		213.4, C
4		116.8, C	4'		85.0, C
5		37.0, C	5'		46.0, C
6	1.04, m 1.65, overlap	37.0, $\text{CH}_2$	6'	1.34, m 1.73, m	32.2, $\text{CH}_2$
7	1.15, m 1.30, m	25.5, $\text{CH}_2$	7'	1.10, m 1.31, m	25.7, $\text{CH}_2$
8	1.24, m	41.4, CH	8'	1.33, m	40.9, CH
9		36.4, C	9'		36.7, C
10	0.95, dd (12.4, 2.0)	54.0, CH	10'	2.24, m	46.4, CH
11	$\beta$ 0.99, m $\alpha$ 1.61, m	34.1, $\text{CH}_2$	11'	$\beta$ 1.22, m $\alpha$ 1.57, m	34.8, $\text{CH}_2$
12	$\beta$ 1.35, overlap $\alpha$ 1.82, overlap	28.0, $\text{CH}_2$	12'	$\beta$ 1.35, overlap $\alpha$ 1.82, overlap	28.0, $\text{CH}_2$
13		45.7, C	13'		45.7, C
14	$\beta$ 1.13, overlap $\alpha$ 1.52, overlap	35.1, $\text{CH}_2$	14'	$\beta$ 1.13, overlap $\alpha$ 1.52, overlap	35.2, $\text{CH}_2$
15		215.4, C	15'		215.5, C
16	4.34, overlap	63.9, $\text{CH}_2$	16'	4.34, overlap	63.9, $\text{CH}_2$
17	1.16, s	20.8, $\text{CH}_3$	17'	1.24, s	20.7, $\text{CH}_3$
18	$\alpha$ 1.73, m $\beta$ 1.99, overlap	16.9, $\text{CH}_2$	18'	2.00-2.10, m (2H)	19.4, $\text{CH}_2$
19	0.90, s	20.7, $\text{CH}_3$	19'	0.78, s	15.7, $\text{CH}_3$
20	0.69, s	12.3, $\text{CH}_3$	20'	0.71, s	12.5, $\text{CH}_3$

**Table S2.**  $^1\text{H}$  (400 MHz) and  $^{13}\text{C}$  (125 MHz) NMR Data for Compound **3** in  $\text{CDCl}_3$ .

No.	$\delta_{\text{H}}$ , multiplets ( $J$ in Hz)	$\delta_{\text{C}}$ , type	No.	$\delta_{\text{H}}$ , multiplets ( $J$ in Hz)	$\delta_{\text{C}}$ , type
1	1.94, m 2.01, m	17.2, $\text{CH}_2$	1'	1.59, m 1.93, m	23.6, $\text{CH}_2$
2	1.97, m 2.24, m	25.8, $\text{CH}_2$	2'	2.11, m 2.70, m	38.2, $\text{CH}_2$
3		145.6, C	3'		213.2, C
4		113.7, C	4'		85.1, C
5		37.0, C	5'		45.7, C
6	1.11, m 1.89, m	37.7, $\text{CH}_2$	6'	1.36, m 1.73, m	32.2, $\text{CH}_2$
7	1.19, m 1.36, m	25.6, $\text{CH}_2$	7'	1.08, m 1.44, m	27.1, $\text{CH}_2$
8	1.33, m	41.2, CH	8'	1.35, m	40.9, CH
9		37.8, C	9'		36.8, C
10	1.06, m	52.2, CH	10'	2.24, dd (11.6, 3.6)	46.5, CH
11	1.15, m 1.58, m	34.8, $\text{CH}_2$	11'	1.18, m 1.59, m	34.9, $\text{CH}_2$
12	$\beta$ 1.42, m $\alpha$ 1.84, m	28.2, $\text{CH}_2$	12'	$\beta$ 1.34, m $\alpha$ 1.93, m	28.2, $\text{CH}_2$
13		45.9, C	13'		45.8, C
14	1.20, m 1.59, m	35.2, $\text{CH}_2$	14'	1.15, m 1.56, m	35.2, $\text{CH}_2$
15		215.5, C	15'		215.7, C
16	4.38, overlap	64.0, $\text{CH}_2$	16'	4.38, overlap	64.0 $\text{CH}_2$
17	1.27, s	21.0, $\text{CH}_3$	17'	1.21, s	20.7, $\text{CH}_3$
18	1.86, m 2.06, m	18.5, $\text{CH}_2$	18'	1.42, m 2.15, m	20.4, $\text{CH}_2$
19	0.90, s	34.1, $\text{CH}_3$	19'	0.82, s	15.9, $\text{CH}_3$
20	0.88, s	12.0, $\text{CH}_3$	20'	0.75, s	12.6, $\text{CH}_3$



**Table S3.**  $^1\text{H}$  (400 MHz) and  $^{13}\text{C}$  (125 MHz) NMR Data for Compound **4** in  $\text{CDCl}_3$ .

No.	$\delta_{\text{H}}$ , multiplets ( $J$ in Hz)	$\delta_{\text{C}}$ , type	No.	$\delta_{\text{H}}$ , multiplets ( $J$ in Hz)	$\delta_{\text{C}}$ , type
1	1.50, m 1.73, m	17.7, $\text{CH}_2$	1'	1.60, m 1.93, m	23.8, $\text{CH}_2$
2	2.05, m 2.25, m	29.7, $\text{CH}_2$	2'	2.11, m 2.74, m	38.6, $\text{CH}_2$
3		143.8, C	3'		213.8, C
4		116.9, C	4'		85.2, C
5		37.2, C	5'		46.2, C
6	1.07, m 1.67, m	37.2, $\text{CH}_2$	6'	1.34, m 1.75, m	32.4, $\text{CH}_2$
7	1.14, m 1.31, m	25.9, $\text{CH}_2$	7'	1.15, overlap 1.36, m	25.8, $\text{CH}_2$
8	1.28, m	41.6, CH	8'	1.28, m	41.3, CH
9		36.9, C	9'		36.6, C
10	1.00, m	54.2, CH	10'	2.25, m	46.5, CH
11	1.04, m 1.62, m	34.3, $\text{CH}_2$	11'	1.15, overlap 1.57, m	35.3, $\text{CH}_2$
12	$\beta$ 1.38, m $\alpha$ 1.87, overlap	29.1, $\text{CH}_2$	12'	$\beta$ 1.41, m $\alpha$ 1.87, overlap	28.1, $\text{CH}_2$
13		45.8, C	13'		38.0, C
14	1.15, overlap 1.58, overlap	35.5, $\text{CH}_2$	14'	1.17, m 1.60, m	36.9, $\text{CH}_2$
15		215.7, C	15'	3.39, dd (10.2, 2.6)	80.9, CH
16	4.39, s (2H)	64.0, $\text{CH}_2$	16'	3.48, dd (10.8, 10.2) 3.78, dd (10.8, 2.6)	48.3, $\text{CH}_2$
17	1.20, s	20.9, $\text{CH}_3$	17'	0.99, s	19.0, $\text{CH}_3$
18	$\alpha$ 1.75, m $\beta$ 2.01, m	17.0, $\text{CH}_3$	18'	2.03, m 2.05, m	19.5, $\text{CH}_2$
19	0.94, s	20.8, $\text{CH}_3$	19'	0.82, s	15.8, $\text{CH}_3$
20	0.73, overlap	12.4, $\text{CH}_3$	20'	0.73, overlap	12.6, $\text{CH}_3$

**Table S4.**  $^1\text{H}$  (400 MHz) and  $^{13}\text{C}$  (125 MHz) NMR Data for Compound **5** in  $\text{CDCl}_3$ .

No.	$\delta_{\text{H}}$ , multiplets ( $J$ in Hz)	$\delta_{\text{C}}$ , type	No.	$\delta_{\text{H}}$ , multiplets ( $J$ in Hz)	$\delta_{\text{C}}$ , type
1	1.51, m 1.70, m	17.7, $\text{CH}_2$	1'	1.58, m 1.94, m	23.8, $\text{CH}_2$
2	2.05, m 2.25, m	29.7, $\text{CH}_2$	2'	2.11, m 2.74, m	38.6, $\text{CH}_2$
3		143.8, C	3'		213.8, C
4		116.9, C	4'		85.2, C
5		37.2, C	5'		46.2, C
6	1.10, m 1.67, m	37.2, $\text{CH}_2$	6'	1.34, m 1.75, m	32.4, $\text{CH}_2$
7	1.16, m 1.33, m	25.9, $\text{CH}_2$	7'	1.15, m 1.36, m	25.8, $\text{CH}_2$
8	1.30, m	41.6, CH	8'	1.32, m	41.2, CH
9		37.0, C	9'		36.8, C
10	1.00, m	54.2, CH	10'	2.23, m	46.6, CH
11	1.04, m 1.64, m	34.3, $\text{CH}_2$	11'	1.15, m 1.58, overlap	35.4, $\text{CH}_2$
12	$\beta$ 1.38, m $\alpha$ 1.58, overlap	29.1, $\text{CH}_2$	12'	$\beta$ 1.41, m $\alpha$ 1.87, m	28.1, $\text{CH}_2$
13		45.8, C	13'		36.6, C
14	1.16, m 1.58, m	35.4, $\text{CH}_2$	14'	0.84, m 1.33, m	36.5, $\text{CH}_2$
15		215.7, C	15'	3.34, dd (9.4, 2.8)	81.4, CH
16	4.38, s (2H)	64.0, $\text{CH}_2$	16'	3.53, dd (10.8, 9.4) 3.78, dd (10.8, 2.8)	62.7, $\text{CH}_2$
17	1.20, s	20.9, $\text{CH}_3$	17'	0.99, s	19.2, $\text{CH}_3$
18	$\alpha$ 1.75, m $\beta$ 2.01, m	17.0, $\text{CH}_3$	18'	2.05, m 2.11, m	19.5, $\text{CH}_2$
19	0.94, s	20.8, $\text{CH}_3$	19'	0.82, s	15.8, $\text{CH}_3$
20	0.73, s	12.4, $\text{CH}_3$	20'	0.73, s	12.6, $\text{CH}_3$

**Table S5.**  $^1\text{H}$  (400 MHz) and  $^{13}\text{C}$  (125 MHz) NMR Data for Compound **6** in  $\text{CDCl}_3$ .

No.	$\delta_{\text{H}}$ , multiplets ( $J$ in Hz)	$\delta_{\text{C}}$ , type	No.	$\delta_{\text{H}}$ , multiplets ( $J$ in Hz)	$\delta_{\text{C}}$ , type
1	1.61, m 2.45, m	34.9, $\text{CH}_2$	1'	1.60, m 1.98, m	23.4, $\text{CH}_2$
2		193.1, C	2'	2.10, m 2.74, m	37.8, $\text{CH}_2$
3		142.4, C	3'		212.7, C
4		143.2, C	4'		85.4, C
5		39.4, C	5'		46.3, C
6	1.32, m 1.77, m	35.9, $\text{CH}_2$	6'	1.37, m 1.82, m	32.1, $\text{CH}_2$
7	1.22, overlap 1.40, overlap	25.1, $\text{CH}_2$	7'	1.22, overlap 1.40, overlap	25.4, $\text{CH}_2$
8	1.36, m	41.0, CH	8'	1.51, m	40.5, CH
9		36.3, C	9'		36.7, C
10	1.58, m	52.6, CH	10'	2.55, dd (12.8, 3.2)	46.0, CH
11	1.08, m 1.60, m	33.7, $\text{CH}_2$	11'	1.20, m 1.56, m	34.7, $\text{CH}_2$
12	$\beta$ 1.43, m $\alpha$ 1.86, m	28.0, $\text{CH}_2$	12'	$\beta$ 1.48, m $\alpha$ 1.86, m	27.7, $\text{CH}_2$
13		45.7, C	13'		45.5, C
14	1.18, m 1.56, m	35.1, $\text{CH}_2$	14'	1.20, m 1.56, m	35.1, $\text{CH}_2$
15		215.5, C	15'		215.1, C
16	4.38, overlap	63.9, $\text{CH}_2$	16'	4.38, overlap	63.9, $\text{CH}_2$
17	1.20, s	20.8, $\text{CH}_3$	17'	1.28, s	20.6, $\text{CH}_3$
18	2.19, m 2.40, m	18.8, $\text{CH}_3$	18'	2.04, m 2.08, m	18.6, $\text{CH}_2$
19	1.10, s	19.1, $\text{CH}_3$	19'	0.85, s	15.9, $\text{CH}_3$
20	0.76, s	12.1, $\text{CH}_3$	20'	0.81, s	12.5, $\text{CH}_3$

**Table S6.**  $^1\text{H}$  (400 MHz) and  $^{13}\text{C}$  (125 MHz) NMR Data for Compound **7** in  $\text{CDCl}_3$ .

No.	$\delta_{\text{H}}$ , multiplets ( $J$ in Hz)	$\delta_{\text{C}}$ , type	No.	$\delta_{\text{H}}$ , multiplets ( $J$ in Hz)	$\delta_{\text{C}}$ , type
1	1.49, m 1.69, m	17.7, $\text{CH}_2$	1'	1.60, m 1.94, m	23.7, $\text{CH}_2$
2	2.01, m 2.22, m	29.8, $\text{CH}_2$	2'	2.13, m 2.74, m	38.4, $\text{CH}_2$
3		143.7, C	3'		213.6, C
4		117.1, C	4'		85.1, C
5		37.2, C	5'		45.8, C
6	1.09, m 1.64, m	37.2, $\text{CH}_2$	6'	1.38, m 1.77, m	32.3, $\text{CH}_2$
7	1.17, m 1.36, m	25.7, $\text{CH}_2$	7'	1.12, m 1.38, m	25.6, $\text{CH}_2$
8	1.22, m	41.7, CH	8'	1.36, m	41.0, CH
9		36.8, C	9'		36.5, C
10	0.98, dd (12.6, 1.8)	54.2, CH	10'	2.26, dd (13.0, 3.4)	46.5, CH
11	1.02, m 1.65, m	34.5, $\text{CH}_2$	11'	1.22, m 1.60, m	34.9, $\text{CH}_2$
12	$\beta$ 1.47, m $\alpha$ 2.00, m	28.9, $\text{CH}_2$	12'	$\beta$ 1.41, m $\alpha$ 1.86, m	28.1, $\text{CH}_2$
13		42.0, C	13'		46.1, C
14	1.24, m 1.66, m	36.1, $\text{CH}_2$	14'	1.20, m 1.56, m	35.2, $\text{CH}_2$
15		184.6, C	15'		215.5, C
			16'	4.39, s (2H)	64.0, $\text{CH}_2$
17	1.26, s	20.9, $\text{CH}_3$	17'	1.24, s	21.4, $\text{CH}_3$
18	1.77, m 2.01, m	17.0, $\text{CH}_3$	18'	2.07, m 2.14, m	19.5, $\text{CH}_2$
19	0.94, s	20.9, $\text{CH}_3$	19'	0.82, s	15.8, $\text{CH}_3$
20	0.74, s	12.4, $\text{CH}_3$	20'	0.75, s	12.6, $\text{CH}_3$

**Table S7.** X-ray Crystallographic Data for Compound **2**<sup>a</sup>

Identification code	cu_20211157_0m
Empirical formula	C <sub>40</sub> H <sub>60</sub> O <sub>6</sub>
Formula weight	636.88
Temperature/K	170.0
Crystal system	triclinic
Space group	P1
<i>a</i> /Å	6.58220 (10)
<i>b</i> /Å	7.3678 (2)
<i>c</i> /Å	19.2597 (5)
<i>α</i> /°	82.8040 (10)
<i>β</i> /°	83.0410 (10)
<i>γ</i> /°	67.3320 (10)
Volume/Å <sup>3</sup>	852.37 (4)
<i>Z</i>	1
$\rho_{\text{calc}}$ g/cm <sup>3</sup>	1.241
$\mu$ /mm <sup>-1</sup>	0.640
<i>F</i> (000)	348.0
Crystal size/mm <sup>3</sup>	0.12 × 0.08 × 0.05
Radiation	Cu K $\alpha$ ( $\lambda$ = 1.54178)
2 $\Theta$ range for data collection/°	4.64 to 148.97
Index ranges	-8 ≤ <i>h</i> ≤ 8, -9 ≤ <i>k</i> ≤ 8, -23 ≤ <i>l</i> ≤ 24
Reflections collected	17711
Independent reflections	6389 [ <i>R</i> <sub>int</sub> = 0.0497, <i>R</i> <sub>sigma</sub> = 0.0520]
Data/restraints/parameters	6389/3/426
Goodness-of-fit on <i>F</i> <sup>2</sup>	1.033
Final <i>R</i> indexes [ <i>I</i> >= 2 $\sigma$ ( <i>I</i> )]	<i>R</i> <sub>1</sub> = 0.0392, $\omega R$ <sub>2</sub> = 0.0977
Final <i>R</i> indexes [all data]	<i>R</i> <sub>1</sub> = 0.0414, $\omega R$ <sub>2</sub> = 0.1001
Largest diff. peak/hole/e Å <sup>-3</sup>	0.22/-0.20
Flack parameter	-0.07 (10)

<sup>a</sup>Crystals of **2** were obtained from CH<sub>2</sub>Cl<sub>2</sub>.

**Table S8.** X-ray Crystallographic Data for Compound **3**<sup>a</sup>

Identification code	cu_2022189_0m
Empirical formula	C <sub>40</sub> H <sub>60</sub> O <sub>6</sub>
Formula weight	636.88
Temperature/K	150.0
Crystal system	monoclinic
Space group	P2 <sub>1</sub>
<i>a</i> /Å	6.9518 (2)
<i>b</i> /Å	14.2638 (3)
<i>c</i> /Å	17.5248 (4)
<i>α</i> /°	90
<i>β</i> /°	93.3940 (10)
<i>γ</i> /°	90
Volume/Å <sup>3</sup>	1734.70 (7)
<i>Z</i>	2
$\rho_{\text{calc}}$ g/cm <sup>3</sup>	1.219
$\mu$ /mm <sup>-1</sup>	0.629
<i>F</i> (000)	696.0
Crystal size/mm <sup>3</sup>	0.08 × 0.05 × 0.03
Radiation	Cu K $\alpha$ ( $\lambda$ = 1.54178)
2 $\Theta$ range for data collection/°	5.052 to 149.04
Index ranges	-8 ≤ <i>h</i> ≤ 8, -17 ≤ <i>k</i> ≤ 17, -21 ≤ <i>l</i> ≤ 21
Reflections collected	30435
Independent reflections	6985 [ <i>R</i> <sub>int</sub> = 0.0428, <i>R</i> <sub>sigma</sub> = 0.0316]
Data/restraints/parameters	6985/1/426
Goodness-of-fit on <i>F</i> <sup>2</sup>	1.045
Final <i>R</i> indexes [ <i>I</i> ≥ 2 $\sigma$ ( <i>I</i> )]	<i>R</i> <sub>1</sub> = 0.0288, $\omega R$ <sub>2</sub> = 0.0730
Final <i>R</i> indexes [all data]	<i>R</i> <sub>1</sub> = 0.0301, $\omega R$ <sub>2</sub> = 0.0739
Largest diff. peak/hole/e Å <sup>-3</sup>	0.21/-0.17
Flack parameter	0.01 (5)

<sup>a</sup>Crystals of **3** were obtained from CH<sub>2</sub>Cl<sub>2</sub>.

**Table S9.** X-ray Crystallographic Data for Compound **4**<sup>a</sup>

Identification code	mo_20211202_0m
Empirical formula	C <sub>40</sub> H <sub>61</sub> ClO <sub>5</sub>
Formula weight	657.33
Temperature/K	170.0
Crystal system	monoclinic
Space group	P2 <sub>1</sub>
<i>a</i> /Å	6.4779 (3)
<i>b</i> /Å	39.9833 (16)
<i>c</i> /Å	7.3091 (3)
<i>α</i> /°	90
<i>β</i> /°	110.8930 (10)
<i>γ</i> /°	90
Volume/Å <sup>3</sup>	1768.64 (13)
<i>Z</i>	2
$\rho_{\text{calc}}$ g/cm <sup>3</sup>	1.234
$\mu$ /mm <sup>-1</sup>	0.151
<i>F</i> (000)	716.0
Crystal size/mm <sup>3</sup>	0.11 × 0.06 × 0.03
Radiation	Mo K $\alpha$ ( $\lambda$ = 0.71073)
2 $\Theta$ range for data collection/°	4.074 to 54.652
Index ranges	-8 ≤ <i>h</i> ≤ 8, -51 ≤ <i>k</i> ≤ 50, -8 ≤ <i>l</i> ≤ 9
Reflections collected	17791
Independent reflections	7158 [ <i>R</i> <sub>int</sub> = 0.0448, <i>R</i> <sub>sigma</sub> = 0.0577]
Data/restraints/parameters	7158/1/423
Goodness-of-fit on <i>F</i> <sup>2</sup>	1.050
Final <i>R</i> indexes [ <i>I</i> ≥ 2 $\sigma$ ( <i>I</i> )]	<i>R</i> <sub>1</sub> = 0.0441, $\omega R$ <sub>2</sub> = 0.0827
Final <i>R</i> indexes [all data]	<i>R</i> <sub>1</sub> = 0.0615, $\omega R$ <sub>2</sub> = 0.0922
Largest diff. peak/hole/e Å <sup>-3</sup>	0.19/-0.27
Flack parameter	-0.06 (4)

<sup>a</sup>Crystals of **4** were obtained from CH<sub>2</sub>Cl<sub>2</sub>.



**Table S10.** X-ray Crystallographic Data for Compound **7**<sup>a</sup>

Identification code	20220561_0m_sq
Empirical formula	C <sub>39</sub> H <sub>58</sub> O <sub>6</sub>
Formula weight	622.85
Temperature/K	170.0
Crystal system	monoclinic
Space group	P2 <sub>1</sub>
<i>a</i> /Å	19.4735 (6)
<i>b</i> /Å	7.8392 (2)
<i>c</i> /Å	24.0193 (8)
<i>α</i> /°	90
<i>β</i> /°	107.264 (2)
<i>γ</i> /°	90
Volume/Å <sup>3</sup>	3501.51 (19)
<i>Z</i>	4
<i>ρ</i> <sub>calc</sub> g/cm <sup>3</sup>	1.182
<i>μ</i> /mm <sup>-1</sup>	0.613
<i>F</i> (000)	1360.0
Crystal size/mm <sup>3</sup>	0.09 × 0.05 × 0.04
Radiation	Cu Kα ( <i>λ</i> = 1.54178)
2 $\Theta$ range for data collection/°	4.752 to 149.498
Index ranges	-24 ≤ <i>h</i> ≤ 24, -9 ≤ <i>k</i> ≤ 9, -29 ≤ <i>l</i> ≤ 30
Reflections collected	58386
Independent reflections	14096 [ <i>R</i> <sub>int</sub> = 0.0598, <i>R</i> <sub>sigma</sub> = 0.0448]
Data/restraints/parameters	14096/62/865
Goodness-of-fit on <i>F</i> <sup>2</sup>	1.060
Final <i>R</i> indexes [ <i>I</i> ≥ 2σ( <i>I</i> )]	<i>R</i> <sub>1</sub> = 0.0616, ω <i>R</i> <sub>2</sub> = 0.1705
Final <i>R</i> indexes [all data]	<i>R</i> <sub>1</sub> = 0.0734, ω <i>R</i> <sub>2</sub> = 0.1821
Largest diff. peak/hole/e Å <sup>-3</sup>	0.48/-0.36
Flack parameter	0.06 (10)


<sup>a</sup>Crystals of **7** were obtained from CH<sub>2</sub>Cl<sub>2</sub>.




**Scheme S1. Plausible biosynthetic pathway for 1–4.**




**Figure S1.** Key COSY, HMBC, and NOESY correlations of 2.




**Figure S2.** Key COSY, HMBC, and NOESY correlations of **3**.




**Figure S3.** Key COSY, HMBC, and NOESY correlations of **4**.




**Figure S4.** Key COSY, HMBC, and NOESY correlations of **5**.




**Figure S5.** The ECD spectra of compounds 4–6.




**Figure S6.** ECD spectra of compound 5 in a DMSO solution (blue) and in a DMSO solution of  $\text{Mo}_2(\text{OAc})_4$  (red) (The inherent ECD was subtracted).



**Figure S7.** Key COSY, HMBC, and NOESY correlations of **6**.




**Figure S8.** Key COSY, HMBC, and NOESY correlations of 7.




**Figure S9.** X-ray ORTEP drawing of 7.

Figure S10. <sup>1</sup>H NMR spectrum of natural Koilodenoid A (**1**) in CDCl<sub>3</sub>.




**Figure S11.**  $^{13}\text{C}$  NMR spectrum of natural Koilodenoid A (**1**) in  $\text{CDCl}_3$ .







**Figure S12.** HSQC spectrum of natural Koilodenoid A (**1**) in CDCl<sub>3</sub>.



**Figure S13.**  $^1\text{H}$ - $^1\text{H}$  COSY NMR spectrum of natural Koilodenoid A (**1**) in  $\text{CDCl}_3$ .



**Figure S14.** HMBC spectrum of natural Koilodenoid A (**1**) in CDCl<sub>3</sub>.



**Figure S15.** NOESY spectrum of natural Koilodenoid A (**1**) in CDCl<sub>3</sub>.




Figure S16. (+)-ESIMS spectrum of natural Koilodenoid A (1).







Figure S17. (+)-HRESIMS spectrum of natural Koilodenoid A (1).



**Figure S18.** IR spectrum of natural Koilodenoid A (1).




**Figure S19.**  $^1\text{H}$  NMR spectrum of Koilodenoid B (**2**) in  $\text{CDCl}_3$ .







**Figure S20.**  $^{13}\text{C}$  NMR spectrum of Koilodenoid B (**2**) in  $\text{CDCl}_3$ .




**Figure S21.** HSQC spectrum of Koilodenoid B (**2**) in CDCl<sub>3</sub>.



**Figure S22.**  $^1\text{H}$ - $^1\text{H}$  COSY spectrum of Koilodenoid B (**2**) in  $\text{CDCl}_3$ .



**Figure S23.** HMBC spectrum of Koilodenoid B (**2**) in CDCl<sub>3</sub>.



**Figure S24.** NOESY spectrum of Koilodenoid B (**2**) in CDCl<sub>3</sub>.




Figure S25. (+)-ESIMS spectrum of Koilodenoid B (2).




Figure S26. (+)-HRESIMS spectrum of Koilodenoid B (2).




Figure S27. IR spectrum of Koilodenoid B (2).









Figure S28. <sup>1</sup>H NMR spectrum of Koilodenoid C (**3**) in CDCl<sub>3</sub>.




**Figure S29.**  $^{13}\text{C}$  NMR spectrum of Koilodenoid C (**3**) in  $\text{CDCl}_3$ .




**Figure S30.** HSQC spectrum of Koilodenoid C (**3**) in CDCl<sub>3</sub>.



**Figure S31.**  $^1\text{H}$ - $^1\text{H}$  COSY NMR spectrum of Koilodenoid C (**3**) in  $\text{CDCl}_3$ .



**Figure S32.** HMBC spectrum of Koilodenoid C (**3**) in CDCl<sub>3</sub>.



**Figure S33.** NOESY spectrum of Koilodenoid C (**3**) in CDCl<sub>3</sub>.




Figure S34. (+)-ESIMS spectrum of Koilodenoid C (3).




Figure S35. (+)-HRESIMS spectrum of Koilodenoid C (3).






Figure S36. IR spectrum of Koilodenoid C (3).




Figure S37. <sup>1</sup>H NMR spectrum of Koilodenoid D (4) in CDCl<sub>3</sub>.







Figure S38.  $^{13}\text{C}$  NMR spectrum of Koilodenoid D (4) in  $\text{CDCl}_3$ .




**Figure S39.** HSQC spectrum of Koilodenoid D (**4**) in CDCl<sub>3</sub>.



**Figure S40.**  $^1\text{H}$ - $^1\text{H}$  COSY NMR spectrum of Koilodenoid D (**4**) in  $\text{CDCl}_3$ .



**Figure S41.** HMBC spectrum of Koilodenoid D (**4**) in CDCl<sub>3</sub>.



**Figure S42.** NOESY spectrum of Koilodenoid D (**4**) in CDCl<sub>3</sub>.




Figure S43. (+)-ESIMS spectrum of Koilodenoid D (4).







Figure S44. (+)-HRESIMS spectrum of Koilodenoid D (4).

Qualitative Analysis Report

Data Filename	ESI202302552.d	Sample Name	D4-RYKH-256F
Sample ID		Position	P1-A1
Instrument Name	Agilent 6520 Q-TOF	Acq Method	20160322_MS_ESIH_POS_1min.m
Acquired Time	4/14/2023 14:24:47	IRM Calibration Status	Success
DA Method	small molecular data analysis method.m	Comment	ESIH by fangsu

User Spectra



Formula Calculator Results

m/z	Calc m/z	Diff (mDa)	Diff (ppm)	Ion Formula	Ion
657.428	657.428	0	0.01	C40 H62 Cl O5	(M+H)+

--- End Of Report ---

Figure S45. IR spectrum of Koilodenoid D (4).







Figure S46. <sup>1</sup>H NMR spectrum of Koilodenoid E (**5**) in CDCl<sub>3</sub>.




**Figure S47.**  $^{13}\text{C}$  NMR spectrum of Koilodenoid E (**5**) in  $\text{CDCl}_3$ .




**Figure S48.** HSQC spectrum of Koilodenoid E (**5**) in CDCl<sub>3</sub>.



**Figure S49.**  $^1\text{H}$ - $^1\text{H}$  COSY NMR spectrum of Koilodenoid E (**5**) in  $\text{CDCl}_3$ .



**Figure S50.** HMBC spectrum of Koilodenoid E (**5**) in CDCl<sub>3</sub>.



**Figure S51.** NOESY spectrum of Koilodenoid E (**5**) in CDCl<sub>3</sub>.






Figure S52. (+)-ESIMS spectrum of Koilodenoid E (5).





Figure S53. (+)-HRESIMS spectrum of Koilodenoid E (5).



**Figure S54.** IR spectrum of Koilodenoid E (**5**).




Figure S55. <sup>1</sup>H NMR spectrum of Koilodenoid F (6) in CDCl<sub>3</sub>.







Figure S56.  $^{13}\text{C}$  NMR spectrum of Koilodenoid F (**6**) in  $\text{CDCl}_3$ .




**Figure S57.** HSQC spectrum of Koilodenoid F (**6**) in CDCl<sub>3</sub>.



**Figure S58.**  $^1\text{H}$ - $^1\text{H}$  COSY NMR spectrum of Koilodenoid F (**6**) in  $\text{CDCl}_3$ .



**Figure S59.** HMBC spectrum of Koilodenoid F (**6**) in CDCl<sub>3</sub>.





**Figure S60.** NOESY spectrum of Koilodenoid F (**6**) in CDCl<sub>3</sub>.




Figure S61. (+)-ESIMS spectrum of Koilodenoid F (6).






Figure S62. (+)-HRESIMS spectrum of Koilodenoid F (6).



**Figure S63.** IR spectrum of Koilodenoid F (**6**).



**Figure S64.**  $^1\text{H}$  NMR spectrum of Koilodenoid G (**7**) in  $\text{CDCl}_3$ .







Figure S65.  $^{13}\text{C}$  NMR spectrum of Koilodenoid G (7) in  $\text{CDCl}_3$ .



**Figure S66.** HSQC spectrum of Koilodenoid G (7) in CDCl<sub>3</sub>.




**Figure S67.**  $^1\text{H}$ - $^1\text{H}$  COSY NMR spectrum of Koilodenoid G (7) in  $\text{CDCl}_3$ .





**Figure S68.** HMBC spectrum of Koilodenoid G (**7**) in CDCl<sub>3</sub>.



**Figure S69.** NOESY spectrum of Koilodenoid G (7) in CDCl<sub>3</sub>.




Figure S70. (+)-ESIMS spectrum of Koilodenoid G (7).




Figure S71. (+)-HRESIMS spectrum of Koilodenoid G (7).




Figure S72. IR spectrum of Koilodenoid G (7).




Figure S73. <sup>1</sup>H NMR spectrum of compound **9** in CDCl<sub>3</sub>.




Figure S74.  $^{13}\text{C}$  NMR spectrum of compound **9** in  $\text{CDCl}_3$ .





Figure S75. (+)-HRESIMS spectrum of compound 9.

### Qualitative Analysis Report

Data Filename	ESI1202202178.d	Sample Name	D4-QA5
Sample ID		Position	PI-A2
Instrument Name	Agilent 66520 Q-ToF	Acq Method	20160322_MS_ESI1_POS_1min.m
Acquired Time	7/7/2022 10:47:21	IRN Calibration Status	Success
DA Method	small_molecular_data_analysis_method.m	Comment	ESI1 by fangsu

#### User Spectra

Fragmentor Voltage: 175  
Collision Energy: 0  
Ionization Mode: ESI



#### Formula Calculator Results

m/z	Calc. m/z	Diff. (mDa)	Diff. (ppm)	Ion Formula	Ion
333.2059	333.206	0.09	0.28	C20 H29 O4	(M+H) <sup>+</sup>

--- End Of Report ---



Figure S76.  $^1\text{H}$  NMR spectrum of synthetic Koilodenoid A (**1**) in  $\text{CDCl}_3$ .




Figure S77.  $^{13}\text{C}$  NMR spectrum of synthetic Koilodenoid A (**1**) in  $\text{CDCl}_3$ .




Figure S78. (+)-HRESIMS spectrum of synthetic Koilodenoid A (1).

